United States: Sarepta Therapeutics And Summit Enter Into Exclusive License And Collaboration Agreement
Last Updated: October 10 2016

WilmerHale client Summit Therapeutics plc and Sarepta Therapeutics announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy. As part of the agreement, Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totaling up to $522 million plus royalties. Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline and Summit retains commercialization rights in all other countries. 

he WilmerHale team representing Summit in this transaction included Partners Steve Barrett and Brian Johnson, Senior Associates Mat Trachok and Scott Lunin and Associate Alex Civetta

Read the formal press release announcing the agreement.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Raya Treiser, Rob Lehman
By Gary Born
By Leila Gaafar
By Timothy Silva, Seth Davis
By Christopher Babbitt, Jonathan Bressler, Claire Chung
By WilmerHale
By Jonathan Yarowsky, Perry A. Lange, Hartmut Schneider, Leon Greenfield, D. Reed Freeman, Jr., Heather Zachary
By Jay Holtmeier, Erin Sloane
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
Font Size: